✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Hikal Ltd.

HIKAL

Market Cap
₹4,267 Cr.
P/E
47.00

Hikal Ltd.

Key Ratios

Edit Ratio's
Market cap
Market cap
4,267 Cr
PE
PE
47.00
Prom Holding
Prom Holding
68.85 %
ROE (%)
ROE (%)
5.86
ROCE (%)
ROCE (%)
8.78
Div Yield (%)
Div Yield (%)
0.35
Sales
Sales
1,859 Cr
OPM (%)
OPM (%)
17.66 %
Debt to Equity
Debt to Equity
0.69
View more
Edit Ratio's
About
Hikal Limited offers solutions across the life sciences value chain. The company is engaged in… Read more
Low
309
52W Range
High
465
  • Hikal
  • Suven Life Sciences
  • Piramal Pharma
  • TJI Pharma - API & CRAMS

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates
Custom financial statementNew
Edit rows
Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

9 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share
40 %
(as of Mar 19)
Source/Historic
Gabapentin - Market Share
Revenue mix

Product Wise Break-Up

Product Wise Break-Up - Pharmaceuticals

Product Wise Break-Up - Crop Protection

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

    locked
    Select a Metric
    • Total reactor capacity (kL)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Corporate Actions
    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less
    Suppliers
    • Balaji Amines Ltd.
    FAQs on Hikal Ltd. Business

    Hikal Limited provides a wide range of solutions in the life sciences value chain including manufacturing chemical intermediates, specialty chemicals, active pharma ingredients, and contract research services to global clients.

    Hikal major competitors are Suven Life Sciences, Piramal Pharma, Cohance Lifesciences, Dishman Carbogen Amc, Sun Pharma Adv. Res, Zenotech Laboratorie, Vivo Bio Tech.
    Market Cap of Hikal is ₹4,432 Crs.
    While the median market cap of its peers are ₹5,264 Crs.

    Hikal seems to be less financially stable compared to its competitors.
    Altman Z score of Hikal is 3.71 and is ranked 5 out of its 8 competitors.

    View FAQ's On Shareprice
    Company Filing
    Discussions & Analysis
    Hikal Ltd.
    View the discussion on ValuePickr
    What Makes Hikal Special - Value Educator
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material